These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25727262)

  • 1. Diagnostics for resource-limited settings in the era of interferon-free HCV therapy.
    Cooke GS; Hill AM
    J Viral Hepat; 2015 May; 22(5):459-60. PubMed ID: 25727262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How will we manage acute HCV in men having sex with men in the era of all oral therapy?
    Boesecke C; Rockstroh JK
    J Viral Hepat; 2015 Jan; 22(1):2-7. PubMed ID: 25333810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment.
    Cohn J; Roberts T; Amorosa V; Lemoine M; Hill A
    Curr Opin HIV AIDS; 2015 Sep; 10(5):369-73. PubMed ID: 26185920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
    Easterbrook P; Sands A; Harmanci H
    Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?
    Mauss S; Rockstroh JK
    J Antimicrob Chemother; 2005 Oct; 56(4):615-8. PubMed ID: 16115826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can hepatitis C virus infection be eradicated in people who inject drugs?
    Grebely J; Dore GJ
    Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus infection management in 2012.
    Van Gulick JJ; Lamers MH; Drenth JP
    Panminerva Med; 2012 Mar; 54(1):1-9. PubMed ID: 22278112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C.
    Mocroft A; Rockstroh J; Soriano V; Kirk O; Viard JP; Caplinskas S; Gasiorowski J; Chiesi A; Phillips AN; Lundgren JD;
    Scand J Infect Dis; 2006; 38(11-12):1092-7. PubMed ID: 17148084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexities of HCV management in the new era of direct-acting antiviral agents.
    Rosenberg WM; Tanwar S; Trembling P
    QJM; 2014 Jan; 107(1):17-9. PubMed ID: 24065837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-free strategies without a nucleoside/nucleotide analogue.
    Welzel TM; Zeuzem S
    Semin Liver Dis; 2014 Feb; 34(1):47-57. PubMed ID: 24782258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Virus in the HIV-infected patient.
    Andersson K; Chung RT
    Clin Liver Dis; 2006 May; 10(2):303-20, viii. PubMed ID: 16971263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir for the treatment of hepatitis C virus infection.
    Adler H; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):725-38. PubMed ID: 24882552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms.
    Cooper CL; Klein MB
    HIV Med; 2014 Nov; 15(10):621-4. PubMed ID: 24802099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.